News from Freeline


Freeline will be progressing to the second dose cohort in the MARVEL-1 study immediately with first patient dosing expected in mid-2022

News from Freeline2022-04-13T15:50:45+02:00

News from Sangamo Therapeutics


Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

News from Sangamo Therapeutics2022-02-08T16:29:44+01:00

News from Freeline


Freeline announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. 

News from Freeline2021-12-13T18:27:08+01:00
Go to Top